Conjugated estrogen alone or with medroxyprogesterone acetate did not affect coronary atherosclerosis progression compared to placebo (mean minimal coronary-artery diameter 1.87 and 1.84 vs 1.87 mm).
RCT (n=309)
Does estrogen replacement therapy (with or without medroxyprogesterone acetate) prevent the progression of coronary atherosclerosis in women with established coronary disease?
Estrogen replacement therapy, with or without medroxyprogesterone acetate, does not slow the angiographic progression of coronary atherosclerosis in women with established coronary disease.
Absolute Event Rate: 1.87% vs 1.87%
p-value: p=not significant
BACKGROUND: Heart disease is a major cause of illness and death in women. To understand better the role of estrogen in the treatment and prevention of heart disease, more information is needed about its effects on coronary atherosclerosis and the extent to which concomitant progestin therapy may modify these effects. METHODS: We randomly assigned a total of 309 women with angiographically verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women were followed for a mean (+/-SD) of 3.2+/-0.6 years. Base-line and follow-up coronary angiograms were analyzed by quantitative coronary angiography. RESULTS: Estrogen and estrogen plus medroxyprogesterone acetate produced significant reductions in low-density lipoprotein cholesterol levels (9.4 percent and 16.5 percent, respectively) and significant increases in high-density lipoprotein cholesterol levels (18.8 percent and 14.2 percent, respectively); however, neither treatment altered the progression of coronary atherosclerosis. After adjustment for measurements at base line, the mean (+/-SE) minimal coronary-artery diameters at follow-up were 1.87+/-0.02 mm, 1.84+/-0.02 mm, and 1.87+/-0.02 mm in women assigned to estrogen, estrogen plus medroxyprogesterone acetate, and placebo, respectively. The differences between the values for the two active-treatment groups and the value for the placebo group were not significant. Analyses of several secondary angiographic outcomes and subgroups of women produced similar results. The rates of clinical cardiovascular events were also similar among the treatment groups. CONCLUSIONS: Neither estrogen alone nor estrogen plus medroxyprogesterone acetate affected the progression of coronary atherosclerosis in women with established disease. These results suggest that such women should not use estrogen replacement with an expectation of cardiovascular benefit.
Herrington et al. (Thu,) conducted a rct in angiographically verified coronary disease (n=309). conjugated estrogen alone or with medroxyprogesterone acetate vs. placebo was evaluated on mean minimal coronary-artery diameter at follow-up (p=not significant). Conjugated estrogen alone or with medroxyprogesterone acetate did not affect coronary atherosclerosis progression compared to placebo (mean minimal coronary-artery diameter 1.87 and 1.84 vs 1.87 mm).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: